INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 450m ago
HOUSE PTR50m ago
SEC 13F50m ago
ROBINHOOD CHAIN49m ago
SEC FORM 4/Grant or awardVerified data

Wheadon David E. reported INDV

Director · Indivior Pharmaceuticals, Inc. · Common Stock

Side
A
Value
—
Shares
5,955
Price
—
Executed
Jan 26, 2026
Disclosed
Jan 28, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 26 executedJan 28, 2026 disclosed

INDV · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 41.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · INDV

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    36
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Open-market purchase
    		BUY$54K
    1,500 sh
    		Aug 27, 2026Aug 27, 2026
    traded Aug 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$707K
    18.6K sh
    		Jun 11, 2026Jun 12, 2026
    traded Jun 11, 2026
    		+1dSEC FORM 4

    Evidence

    23
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.36M
    36.0K sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    17
    RB
    Ryan BarbaraDirector
    INDVIndivior Pharmaceuticals, Inc.
    Grant or award
    		A—
    6,518 sh
    		May 13, 2026May 14, 2026
    traded May 13, 2026
    		+1dSEC FORM 4

    Evidence

    17
    HK
    Humphreys KeithDirector
    INDVIndivior Pharmaceuticals, Inc.
    Grant or award
    		A—
    6,518 sh
    		May 13, 2026May 14, 2026
    traded May 13, 2026
    		+1dSEC FORM 4

    Evidence

    28
    Gilbert Ray Cisneros, Jr.DSelf
    SUPNIndivior Pharmaceuticals, Inc.
    Purchase
    		BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
    traded Mar 3, 2026
    		+35dHOUSE PTR

    Evidence

    9
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    6,302 sh
    		Mar 14, 2026Mar 17, 2026
    traded Mar 14, 2026
    		+3dSEC FORM 4

    Evidence

    9
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    6,302 sh
    		Mar 14, 2026Mar 17, 2026
    traded Mar 14, 2026
    		+3dSEC FORM 4

    Evidence

    12
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$88K
    2,843 sh
    		Mar 14, 2026Mar 17, 2026
    traded Mar 14, 2026
    		+3dSEC FORM 4

    Evidence

    27
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$265K
    8,283 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    30
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$2.80M
    87.6K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    17
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    86.9K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    113.5K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    101.5K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    26
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$1.46M
    45.8K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    18.4K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    17
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    5,946 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    24.0K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    5,946 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    132.6K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001789507-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 26, 2026
    Published
    Jan 28, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Wheadon David E.
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Indivior Pharmaceuticals, Inc.
    Ticker
    INDV
    Shares
    5,955
    Price per share
    $0
    Execution date (reported)
    Jan 26, 2026
    Owned after transaction
    20.4K shares
    Days from execution to publication
    2

    What this establishes

    Wheadon David E. filed this Form 4 reporting a grant or award of INDV on Jan 26, 2026. It became public on Jan 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Wheadon David E.cik:0001789507
    Issuer
    Indivior Pharmaceuticals, Inc.cik:0001625297

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.